Nick Manusos, CEO of Kenai Therapeutics, said, "We are a syndicate consisting of leading life science investors and co-founders and scientists Dr. Howard Federoff and Jeffrey. I am grateful for the support of the veteran team in the industry, including Dr. Corder. All of you who cooperated are confident that our approach will open up the future of the treatment of central nervous system disorders. Our lead candidate drug RNDP-001 will be introduced in the clinical field of Parkinson's disease treatment soon, but we will continue to cherish your valuable guidance in the future."

RNDP-001 is an iPSC-derived heterogeneous dopamine precursor cell therapy for the treatment of both idiopathic and hereditary Parkinson's disease, robust survival, neurocontrol, and behavioral relief in the preclinical model of Parkinson's disease. I showed it. With the proceeds from the funding, we can submit the RNDP-001 IND and complete the Phase 1 clinical trial, which is scheduled to start later this year.

Dr. Jeff Jonas, chairman and director of Kenai Therapeutics and a partner of Cure Ventures, said, "Kenai's unique platform is a neuronero lost due to neurodegeneration. By replacing n, we are taking advantage of a new approach to treating central nervous system disorders. The potential healing effect of RNDP-001 on Parkinson's disease may dramatically change the outcome of patients with few treatment options."

In addition to RNDP-001, Kenai is developing a robust pipeline of advanced existing dopamine and neuron replacement cell therapies for neurological diseases. We plan to work together with Fujifilm Cellular Dynamics, a leading expert in iPSC technology research and contract manufacturing partner, in manufacturing and development services in the future.

Tomoyuki Hasegawa, president and chief executive officer of Fujifilm Cellular Dynamics, said, "Our company, a world leader in the iPS cell field, the Kenai Therapeutics team is targeting patients with neurodegenerative diseases, I am happy to support you to make progress in this promising scientific field."

Jeff Goter, a partner of The Column Group, said, "Kenai's approach to treating Parkinson's disease is largely differentiated from competing cell therapy approaches, mainly symptomatic treatment choices. There is a possibility of modifying the disease for patients with limited limbs. We are proud to support Kenai's mission to promote RNDP-001 to help patients and their families suffering from this destructive disease."